echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Zejing pharmaceutical, the fifth set of standard enterprises, officially launched the IPO, with full confidence

    Zejing pharmaceutical, the fifth set of standard enterprises, officially launched the IPO, with full confidence

    • Last Update: 2020-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network pharmaceutical stock market] on January 6, 2020, Zejing pharmaceutical officially launched the offering, which also means that the first unprofitable listed company will be welcomed in the A-share market In fact, as the first company applying for listing with the fifth set of standards, the listing process of Zejing pharmaceutical has always been concerned by the market On December 31, 2019, China Securities Regulatory Commission (CSRC) approved the registration of the public issuance of shares of Zejing pharmaceutical innovation board, which means that Zejing pharmaceutical, an innovative pharmaceutical enterprise, has passed the examination of Shanghai Stock Exchange and the registration of CSRC, and will soon become the first listed company in the fifth set of standards of science and technology innovation board In the evening of January 5, 2020, Zejing pharmaceutical released the announcement of issuance arrangement and preliminary inquiry, and officially launched the issuance According to the prospectus, Zejing biology is an innovation driven chemical and biological new drug R & D enterprise focusing on tumor, hemorrhage, blood disease, hepatobiliary disease and other treatment fields All products of the company are in the stage of R & D, no commercial production and sales have been carried out, no sales revenue has been realized for the company's products, and the company has not yet made profits and accumulated losses have not been made up During 2016-2018, the net profit of Zejing biological's parent company is - 130 million yuan, - 150 million yuan and - 440 million yuan respectively From January to June 2019, the net profit of the company's parent company is - 340 million yuan In addition, the company is expected to have accumulated and unrepaired losses in the future and will continue to make losses It is worth noting that Zejing biological has a rich pipeline of innovative drugs As of December 9, 2019, the company is carrying out 29 research projects of 11 innovative drugs, including donafinil toluenesulfonate tablets, recombinant human thrombin for external use, Jack TiNi hydrochloride tablets and okatini capsules, which have multiple indications in II / III respectively Phase I clinical trial stage: recombinant human thyrotropin for injection and Jack TiNi hydrochloride cream are in phase I clinical trial stage; the combination of donafinil toluene sulfonate and anti-PD-1 antibody has obtained the notice of clinical trial; Jack TiNi hydrochloride has submitted ind application for the treatment of a variety of autoimmune diseases; small molecule new drugs zg5266, zg0588, zg170607, double targets for anti-tumor New antibody drugs zg005 and zg006 are in the pre clinical development stage In addition, the company expects that from 2020 to 2023, many indications of 4-5 innovative drugs will be applied for marketing With these new drugs coming into the market, the company's sales revenue is expected to meet considerable growth and become a high growth innovative pharmaceutical enterprise with considerable revenue   In the view of the insiders, Zejing pharmaceutical, the first loss making enterprise, is about to become the first listed company in the fifth set of standards of science and technology innovation board, which fully reflects the support and encouragement of science and technology innovation board for the issuance and listing of "hard science and technology" enterprises Multiple listing conditions can meet the issuance and listing needs of different types of science and technology innovation enterprises, which is conducive to enhancing the capital market tolerance and improving the service innovation driven war A little bit of power However, some industry insiders also remind that inclusiveness is a bright spot of the science and technology innovation board, but it should be noted that, while relaxing the threshold requirements of listed financial indicators, there may also be some companies with low technology content "fishing in troubled waters", so the quality of listed companies needs to be improved According to statistics, a total of 30 enterprises applying for the science and technology innovation board have chosen the non-profit listing standard In addition to Zejing biology, six companies, including baiaotai (submitted for registration), tianzhihang, Qianfeng biology, Shenzhou cell, Junshi biology, have lost money or have not generated sales revenue Among the listed companies, two companies, shanshiwangke and microchip biology, have accumulated but not made up for their losses.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.